Overview of Antimal

Quick Facts

Property	Description
Active Ingredients	Lumefantrine, Artemether
Form	Oral Tablet (Fixed-Dose Combination)
Pharmacological Class	Antimalarial / Blood Schizonticide
Common Use	Uncomplicated Plasmodium falciparum malaria
Origin	Synthetic Organic Compound

Antimal: A Clinically Recognized Antimalarial Combination

Antimal is a prescription medication, chemically synthesized and classified as an antimalarial drug, specifically a Blood Schizonticide, designed for oral administration. It represents a modern Artemisinin-based Combination Therapy (ACT). As a result, the combination approach is recognized as an essential, first-line tool against the disease.

The drug is a fixed-dose combination product containing two active chemical entities: Lumefantrine and Artemether. This dual-ingredient strategy is recognized for its role in mitigating the development of drug resistance, offering an advantage over single-agent therapies. By combining components with distinct action profiles, Antimal ensures a more robust and complete attack on the parasitic organism responsible for the infection.

Composition and Form of the Oral Tablet

Antimal is supplied as an oral dosage form, specifically a tablet, where both active ingredients are permanently combined in precise, balanced quantities. Both Lumefantrine (an aryl amino alcohol) and Artemether (an artemisinin derivative) are synthetic organic compounds derived through complex chemical synthesis.

The necessity of the fixed-dose tablet design serves a vital public health function, guaranteeing that the patient receives the necessary ratio of both agents with every administration. Lumefantrine's high lipophilicity and long half-life are features integrated into the formulation to ensure sustained action against residual parasites.

General Purpose and Dual-Action Strategy

The general purpose of Antimal is to effectively stop the rapid multiplication of the parasitic organisms responsible for uncomplicated malaria in the patient's bloodstream, a typical use scenario for this ACT class. This goal is achieved through a dual-action strategy leveraging the unique time-action profiles of its components.

The treatment relies on Artemether for its rapid-acting effect, providing a swift initial reduction in the parasite population, while Lumefantrine is long-acting, persisting in the body to eliminate any residual parasites, thereby reducing the chance of recurrence.

Regulatory References

Artemether + lumefantrine - eEML

What side effects are possible with Antimal?

Possible Side Effects and Safety Information

The official safety profile for the fixed-dose combination of Lumefantrine and Artemether is structured according to regulatory classifications, detailing potential adverse reactions by frequency and physiological system. These events are grouped into System-Organ-Classes (SOCs) such as Nervous System Disorders, Gastrointestinal Disorders, Cardiac Disorders, and Hepatobiliary Disorders.

The most frequently observed adverse reactions are classified as Very Common (ge 1/10), including headache and dizziness. Side effects listed as Common (ge 1/100 to < 1/10) include sleep disturbances, gastrointestinal discomfort (nausea, vomiting, diarrhea), fatigue, myalgia, and palpitations. These systemic effects are often noted as being more frequently observed at the beginning of treatment.

The most significant safety consideration documented in regulatory labeling relates to the potential for Prolongation of the QTc Interval, an effect associated with the long-acting component, Lumefantrine, which carries a theoretical risk of serious ventricular arrhythmias.

Safety Constraints and Considerations

Official documents mandate specific limitations for use. The drug is contraindicated in patients with severe hepatic impairment and those with pre-existing conditions that prolong the QTc interval, such as congenital QTc prolongation, relevant bradycardia, or uncorrected hypokalemia or hypomagnesemia. Furthermore, co-administration with other medicines known to significantly affect the QTc interval is restricted due to the combined risk.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented risks and required actions in the event of an overdose with Antimal (Lumefantrine/Artemether), based strictly on regulatory prescribing information.

Documented Overdose Manifestations

An overdose is typically associated with an exaggeration of known drug effects. The primary official concern is the potential for QT interval prolongation, an electrical change visible on an electrocardiogram (ECG), which can lead to serious cardiac rhythm problems (arrhythmias).

Other regulator-listed manifestations may include an increased intensity of common symptoms, such as headache, vomiting, dizziness, and asthenia (weakness).

Required Emergency Actions

In the event of a suspected overdose, immediate medical attention is mandatory. Patients or caregivers must contact a Poison Control Center or emergency medical services (e.g., 911 or equivalent) without delay.

Treatment is supportive, as no specific antidote is officially documented. Regulatory guidance requires immediate hospital monitoring, including continuous ECG monitoring of the patient's heart function. Supportive measures, such as the removal of unabsorbed drug via gastric lavage or activated charcoal, should also be administered by healthcare professionals.

Therapeutic Uses of Antimal

Treating Acute Malaria: Uses and Patient Benefits

Antimal is commonly used to help with acute, uncomplicated malaria specifically caused by the parasitic species Plasmodium falciparum in patients weighing at least 5 kg. This medication is relevant for managing the condition in geographical regions where symptoms may intensify temporarily due to resistant parasitic strains. The dual-component therapy is applied in addressing conditions presenting with systemic or localized discomfort and is considered relevant for managing the condition across eligible patient groups, including children.

The core therapeutic domain is used for managing infection by achieving parasite clearance. The combination may assist with easing the intensity of symptoms related to systemic imbalance, such as fever and chills, alongside symptoms related to physical discomfort like headache and muscle aches. Symptomatic relief supports the patient in coping more steadily with the acute phase and contributes to easing the overall symptom load.

Quick Fact: Supportive Symptom Management

Eligibility and Restrictions for Use

Who Can and Cannot Use Antimal?

Regulatory documents define specific populations who are eligible, restricted, or prohibited from using Antimal. The medicine is approved for treating uncomplicated Plasmodium falciparum malaria in patients weighing 5 kilograms (about 11 pounds) or more.

Contraindicated Populations (Must Not Use)

The medicine is strictly contraindicated and must not be used in the following groups:

Patients with severe malaria, as defined by the World Health Organization (WHO).
Patients with a known hypersensitivity to artemether, lumefantrine, or any components.
Individuals with a family history of QTc interval prolongation or sudden death, or those with existing cardiac conditions known to prolong the QTc interval (e.g., severe heart disease, certain antiarrhythmic drugs).

Restricted and Conditional Use

Age/Weight: Not established for infants weighing less than 5 kg.
Pregnancy: Not recommended during the first trimester of pregnancy if suitable alternative treatments are available.
Organ Function: Caution should be exercised in patients with severe hepatic or renal impairment, as clinical safety data are limited in these groups. Use is generally permitted in mild to moderate impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

It is important to inform your healthcare provider about all prescription, over-the-counter (OTC), and herbal medications you are currently taking before starting Antimal therapy. This is crucial as Antimal can interact with a wide range of products, potentially altering its effectiveness or increasing the risk of adverse effects.

Significant Drug Interactions

Antimal is primarily metabolized by certain cytochrome P450 (CYP) enzymes, particularly CYP2D6 and CYP3A4. Therefore, medicines that inhibit or induce these enzymes can significantly affect Antimal's plasma concentrations.

CYP2D6/CYP3A4 Inhibitors (e.g., certain antifungals, macrolide antibiotics, protease inhibitors): These can increase Antimal's levels, heightening the risk of dose-related side effects such as QT prolongation and cardiotoxicity.
CYP2D6/CYP3A4 Inducers (e.g., certain anticonvulsants, rifamycins): These can decrease Antimal's levels, potentially leading to treatment failure.

Other Notable Interactions

Product Category	Example Agents	Potential Effect
QT-prolonging drugs	Amiodarone, Haloperidol	Increased risk of severe cardiac arrhythmias.
Hepatotoxic agents	Paracetamol (high doses), Methotrexate	Elevated risk of liver injury.

It is also generally recommended to avoid grapefruit juice and St. John’s Wort as they can interfere with the metabolism of Antimal. Always discuss potential drug-drug and drug-food interactions with a pharmacist or physician.

Mechanism of Action

How Antimal Works: Mechanism of Action

Antimal exerts its effect primarily by acting as an inhibitor within the food vacuole of the target organism. Its main biological target is ferriprotoporphyrin IX (heme), a toxic byproduct generated from the digestion of hemoglobin. The drug prevents the organism's detoxification pathway from converting this toxic heme into non-toxic hemozoin.

The resulting accumulation of toxic, unprocessed heme leads to the generation of reactive oxygen species (oxidative stress) and direct damage to the organism's membranes and organelles. This mechanistic cascade results in the lysis (destruction) of the organism.

Additionally, Antimal introduces disruption to key intracellular pathways, interfering with the synthesis of DNA and proteins. This complementary action limits the organism's capacity for replication and maturation. The combined physiological consequences of cellular destruction and limited proliferation reduce the organism load within the host.

Dosage and Administration Information

How to Use Antimal: Administration Guidelines

Antimal, a fixed-dose combination tablet containing Artemether and Lumefantrine, is utilized for oral administration as a structured, short-term treatment. The standard usage protocol is a 3-day course that requires a total of six doses, a regimen designed to achieve complete parasite clearance.

Dosing Protocol and Schedule

The required dose is defined by patient weight. For adults and pediatric patients weighing 35 kg or greater, the dose is standardized at four tablets per intake. Pediatric patients weighing 5 kg up to 35 kg require a lower number of tablets per dose based on a weight-band-specific protocol. The standard schedule begins on Day 1 with two doses: an initial dose (0 hours) followed by a second dose 8 hours later. On Day 2 and Day 3, a dose is taken twice daily (morning and evening).

Administration Conditions and Handling

Every dose of Antimal is to be taken with food or a high-fat liquid (such as milk or formula) to significantly improve the absorption of the Lumefantrine component, a requirement for the medicine's proper action. If a patient is unable to swallow the tablet, the dose may be crushed and mixed with a small amount of water for immediate ingestion; this should also be followed by food. If any dose is vomited within 1 to 2 hours of administration, the full dose is typically repeated immediately to maintain the required concentration for treatment.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Antimal

Evidence for Use in Acute, Uncomplicated Plasmodium falciparum Malaria

The research for Antimal (artemether/lumefantrine) primarily consists of numerous Randomized Controlled Trials (RCTs) and Systematic Reviews that synthesize the results of those trials. This drug combination was evaluated in research exploring treatment for individuals presenting with acute, uncomplicated malaria caused specifically by the Plasmodium falciparum parasite. The studies examined key measures, such as the time needed for the parasite to be cleared from the bloodstream and the proportion of patients assessed for an Adequate Clinical and Parasitological Response (ACPR) at specific follow-up points.

Research reports observations from patients included in clinical studies across diverse geographic settings with varying levels of malaria transmission. Findings describe the patterns of parasite clearance measured after the start of treatment. Research highlights changes measured during the study period, which help contextualize how the combination fits within the broader evidence landscape for antimalarial therapies.

Study Focus on Symptom and Parasite Clearance

In the trials, researchers monitored two main axes of response: parasite clearance and symptom resolution. Specifically, studies explored the Time to Parasite Clearance (PCT) and the Time to Fever Clearance (FCT), tracking other outcomes related to outcomes related to systemic or functional imbalance, such as headache and general malaise.

Research provides insight into short-term changes, documenting that the rapid-acting component was associated with observed reductions in the rate of parasite count. Findings describe patterns observed in the studies related to fever resolving within the initial days of treatment. This evidence contributes to understanding the patterns observed during the acute phases of the condition.

Evidence in Special Populations: Children and Pregnant Women

Antimal was evaluated in specific patient populations, including children weighing ge 5 kg and pregnant women in the second and third trimesters. Research describes that specific formulations were studied to address the distinct physiological needs of these groups. Findings indicate that in some studies involving very young, underweight children and pregnant women, the drug's presence (exposure) in the body was observed to be lower than in non-pregnant adults. This variation in exposure was observed in some studies to be associated with reduced Adequate Clinical and Parasitological Response (ACPR) in these specific groups. Results apply only to the populations studied, and data for certain groups, particularly those who are underweight or in the first trimester of pregnancy, remain insufficient or limited.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Antimal (FAQ)

Q: How quickly does Antimal start working after the first dose?

Official information describes one of Antimal's components, artemether, as having a rapid onset of action. This rapid action is designed to quickly reduce the number of malarial parasites in the blood, which is associated with rapid symptomatic relief observed in clinical studies.

Q: How long does the effect of Antimal last in the body?

The medicine is a fixed-dose combination that contains a long-acting component called lumefantrine. Official prescribing information describes lumefantrine as having a long elimination half-life in the body. This characteristic is intended to help support sustained action and clear any residual parasites after the initial treatment course.

Q: Is it normal to feel slightly dizzy when first starting Antimal?

Official regulatory documents list dizziness as a Very Common side effect of this medication. These types of systemic effects are generally described as being more frequently observed at the beginning of the treatment course.

Q: Is it safe to take Antimal with vitamins or herbal supplements?

Regulatory documents advise patients to inform their healthcare provider about all prescription, over-the-counter, and herbal products they are taking. Official documents list St. John’s Wort as a product that should be avoided, as it may interfere with how Antimal works in the body.

Q: Can Antimal be used by older adults (e.g., over 65)?

Some international regulatory documents note that there is no information suggesting that the required dose for patients over 65 years of age should be different from that of younger adults. This indicates that it is a population where use is permitted under professional guidance.

Q: Has Antimal been studied in pregnant or breastfeeding populations?

Research documents describe the evaluation of Antimal in pregnant women in the second and third trimesters. However, official information also notes that the medicine has not been specifically studied in nursing mothers (breastfeeding populations).

Q: What should I do if I notice a change in my vision while using Antimal?

Official patient information leaflets consistently state the importance of informing a healthcare provider immediately of any change in health status. Official guidance states that a healthcare provider should be contacted if you notice any such effects.

Q: What happens if I stop taking Antimal suddenly?

Official instructions state that treatment should be followed for the full prescribed duration. Stopping the medicine too soon may result in the infection not being completely cured or the return of the condition.

Q: Is Antimal used for anything besides its main listed purpose?

Regulatory documents list the official indication as the treatment of acute, uncomplicated Plasmodium falciparum malaria. Official statements also explicitly clarify that the product is not approved for the prevention of malaria or the treatment of severe malaria.

Q: Are there different strengths of Antimal available?

Official regulatory documentation describes two main types of tablets, each containing a fixed ratio of artemether and lumefantrine. These different tablet strengths are designed to facilitate dosing across various weight bands, such as for smaller pediatric patients versus adults.

Q: Can Antimal cause weight changes (gain or loss)?

Regulatory documents list decreased appetite as a Very Common adverse reaction to this medication. While weight changes are not listed directly, changes in appetite are a symptom that could potentially be associated with changes in weight.

Q: Are there any known interactions between Antimal and birth control pills?

Official patient information indicates that Antimal can decrease how well birth control pills with hormones in them work. This potential interaction may increase the risk of unintended pregnancy.

Q: What happens if someone accidentally takes too much Antimal?

Official instructions state that if too many tablets are taken, a healthcare provider or the nearest hospital emergency department should be contacted for further advice and monitoring.

Q: Is there any evidence about Antimal being effective in preventing its target condition?

Official documentation explicitly states that Antimal is not approved for the prevention of malaria. The medicine is authorized and studied solely for the treatment of an existing acute infection.

Q: Are the side effects of Antimal permanent, or do they go away?

Official patient leaflets often describe most side effects as mild to moderate in nature. These effects generally disappear after a few days to a few weeks once the patient has completed the short course of treatment.

Q: Does Antimal have any effect on mental clarity or concentration?

Regulatory documents list several effects that can impact mental functions, including dizziness, somnolence (sleepiness), and fatigue/asthenia. If a patient experiences these, they may notice an impact on their concentration.

Q: What are the main research themes discussed in official evidence reports for Antimal?

The primary themes of research described in official documents focus on key efficacy measures such as the Parasite Clearance Time (PCT), the Fever Clearance Time (FCT), and the overall rate of Adequate Clinical and Parasitological Response (ACPR).

Q: Why is Antimal sometimes prescribed when other drugs seem more common?

Antimal is classified as an Artemisinin-based Combination Therapy (ACT), an approach widely supported by the World Health Organization. Regulatory documents note that the drug has been shown to be effective in regions where resistance to other common antimalarials has been reported.

Q: Is Antimal suitable for people with heart conditions?

Antimal is strictly contraindicated and must not be used in individuals with pre-existing cardiac conditions that are known to prolong the QTc interval. These conditions include severe heart disease or certain types of rhythm disturbances.

Q: How does Antimal's half-life relate to how often it needs to be taken?

The fixed 3-day, six-dose regimen is designed to utilize the distinct time profiles of the two components. The schedule is designed to leverage the rapid-acting component first while maintaining the long-acting component in the body at the necessary concentrations for sustained parasite clearance.

Q: Are there any restrictions on driving or operating machinery while taking Antimal?

Official regulatory warnings state that Antimal may cause side effects such as dizziness and tiredness/fatigue. If these effects occur, product information states that individuals should refrain from driving or operating any tools or machines.

How should Antimal be stored and disposed of?

How to Store and Dispose of Antimal

Antimal tablets must be stored strictly at room temperature, ensuring the temperature does not exceed 30 °C.

Storage Requirements

Environment: The product must be kept from freezing and protected from both excess heat and moisture. It also requires protection from light.
Packaging: Tablets must remain in their original container and be stored in the blisters in the provided carton. The container should be tightly closed.
Stability: Once a tablet is removed from its blister and prepared for use, it must be administered immediately.
Safety: This medicine must be kept out of the sight and reach of children.

Disposal

Unused or expired Antimal must not be flushed down the toilet. The preferred method for disposal is through an official medicine take-back program. If a program is unavailable, the unneeded medication should be mixed with an undesirable substance, such as used coffee grounds, placed in a sealed bag or container, and discarded in the household trash.

Antimal